

Mission

Axxam is aiming to become a worldwide leading discovery company within the life science industry

Discovery Services

- Assay Development
- High-Throughput Screening
- Compound Profiling
- Hit-to-lead
- Compound collection for custom screening

Discovery Research

- Proprietary programs in selected therapeutica areas, available for licensing

Technologies

- Novel Photoproteins
- chAMPion technology
- Stem cells for HTS
- PhotoTopo® transgenic animal

From Genes to Leads

Axxam is a **discovery company** focused on research programs for different applications in the life science industry, including pharmaceutical, agrichemical and flavour fields.

Discovery Services

Axxam provides an integrated and highly skilled team of scientists to speed and support our clients' discovery process from genes to leads. Axxam's services meet the very highest quality standards and practices in the following fields:

- Assay Development
- High-Throughput Screening
- Compound Profiling
- Hits-to-Leads

Assay Development

Axxam cell biologists and biochemists develop assays optimized for screening campaigns to be run either in your laboratory or at Axxam on one of our automated screening stations. Each assay is carefully optimized to guarantee sensitive and robust results, taking into account the unique needs and capabilities of each partner. Axxam cell biologists offer their expertise for development of HTS grade assays in the following target classes:

- GPCRs
- Ion Channels
- Receptor Tyrosine Kinases
- Transporters
- Cytokine Receptors
- Enzymes
- Nuclear Hormone Receptors

High-Throughput Screening

Axxam's labs are equipped with **two state-of-the-art screening stations** designed for running 384 MTP format biochemical and cell based assays using luminescent or fluorescent based readouts. We offer the highest level of expertise and knowledge in configuration of the assay to make the most of every screening campaign.

Compound Collections for customer screening

We can conduct high-throughput screening by using:

- Library provided by the client – we screen compound collections that you supply in 384-MTP.
- Axxam Synthetic Compound Collection – we screen our library composed of more than 140,000 different synthetic compounds.
- Natural Compound Collection – we screen a collection of more than 500,000 different natural compounds available to Axxam from our partner (InterMed Discovery GmbH).

Compound Profiling


Axxam offers compound profiling analyses for a number of attractive pharmaceutical target classes.

More than **200 functional cell-based and biochemical assays** are available.

The sensitivity of the assays ensures detection of even minor differences in activity between compounds to facilitate ultimate compound selection for your drug development programs.

Hit-to-lead

Axxam provides a comprehensive and detailed Hits to Leads service to maximize the results from your primary screening campaign. We have an extensive range of orthogonal assay formats that can be applied to weed out the false positive results, and confirm the real hits. We apply our in-depth knowledge of target biology and small molecule chemical analysis to define the most promising structures and scaffolds to take forward in your Lead Optimization programs.



Technologies

Axxam is constantly evolving and developing new approaches and concepts to address the salient challenges presented by modern day discovery research.

We have invested a significant proportion of our resources into the development of **innovative technologies** and tools for enabling the discovery process to successfully overcome the many challenges faced by life sciences companies

Axxam has built a strong IP Portfolio of technologies and applications, which are applied to our services activities and discovery programs.

Our patent portfolio includes new technologies and tools for High Throughput Screening, detection methods and primary and stem cells for discovery.

Discovery Programs

Axxam is taking advantage from its state-of-the-art discovery platforms for conducting several programs to identify bioactive compounds for applications in pharma, agrichemical and flavour.

Our pharma discovery programs are aimed at identifying proprietary pre-clinical candidates in selected therapeutic areas, available for licensing.

Partnering and licensing opportunities

Please contact us for partnering opportunities of our discovery services programs and other technology licensing opportunities.

Business Model

Our business model combines internal research programs with our comprehensive range of from genes to leads discovery services, products and technologies.

We offer two options for companies to work with us:

1. on a fee-for-service basis for our complete range of drug discovery services and technologies;
2. or in customized partnership arrangements involving risk-sharing, milestone payments and/or royalties.

History

Bayer established an advanced technology group at the San Raffaele Biomedical Science Park, Milan in 1995. The Milan group became recognized as a leader in assay development and evolved into the assay factory within the world-wide R&D organization of Bayer Group with specialized and dedicated laboratories for the development of specific ultra high-throughput screening assays. The group later developed additional expertise in bioinformatics and target biology.

In late 2001 Axxam became independent of Bayer to become a discovery partner for the life science industry.

Executive Directors

Stefan Lohmer

Chief Executive Officer
Chairman
Co-Founder

Alessandro Sidoli

Chief Executive Officer
Co-Founder

Luigi Gavazzeni

Chief Financial Officer

Corporate Offices & Laboratories

San Raffaele Biomedical Science Park
Milan, Italy

Industry Affiliations

Assobiotec
Farindustria

Contacts (Business Development)

Sabrina Corazza
phone +39 335 8707129
email sabrina.corazza.sc@axxam.com

Axxam SpA

San Raffaele Biomedical Science Park
via Olgettina 58
20132 Milan, Italy

phone + 39 02 210561
fax + 39 02 2105602

www.axxam.com